Biotech News

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Acasti Pharma (ACST)Acasti Pharma2026-06-25 13:46 ESTFDA / regulatory

ACST (ACST) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is acst.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

ACSTAcasti Pharma2026-06-25 13:46 EST

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

View all latest news

Acasti Pharma

Acasti Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ACSTAcasti Pharma2026-06-26 13:29 EST

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

ACSTAcasti Pharma2026-06-26 13:29 EST

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

ACSTAcasti Pharma2026-06-26 13:29 EST

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

ACSTAcasti Pharma2026-06-26 13:29 EST

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

ACSTAcasti Pharma2026-06-26 13:29 EST

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States